Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RLMD Relmada Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $3.72 -1.3% | $16.02 -1.8% |
| StockIQ Score | 45D+ Moderate Risk: High | 42D Weak Risk: Medium |
| Technical | 9F | 36F |
| Fundamental | 46D+ | 35F |
| Growth | 66B- | 50C- |
| Fair Value | 50C- | 38F |
| News | 92A+ | 50C- |
| Quality | — | 50C- |
| Risk | 40D | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Relmada Therapeutics (RLMD) outperforms Ascentage Pharma (AAPG) in growth and fundamentals, with scores of 66 and 46 versus 50 and 35. RLMD also has a stronger investor rating (Moderate vs. Weak) and a higher fundamental score. AAPG leads only in technicals (36 vs. 9) and valuation (38 vs. 50), but RLMD’s growth score is notably higher.
